Sorrento intends to combine a variety of its proprietary mAbs in conjunction with the ADNAB technology platform... Apr 28
Sorrento receives USFDA clearance to start a clinical trial of Anti-CD47 Antibody, discovered from fully human G-MAB library, for treatment of multiple malignancies ... Mar 03
Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) platform exclusive license from Sorento... Sep 15
Registers total 93,406 fatalities according to the real-time tally by Johns Hopkins University... May 21
-Advertisements-